Frontlight ResearchEarly access
CompletedNo phase
Antireflux Ablation of the Cardia Mucosa vs Placebo for the Treatment of Gastroesophageal Reflux Disease
Key facts
- Who runs it
- Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
- Where
- Spain9 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 64 people enrolled
- Started
- 1 Mar 2021
- Ended
- 7 Feb 2025
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- ARMA (antireflux ablation of the cardiac mucosa)
- upper digestive endoscopy
- Record updated
- 24 April 2025
Who can take part
- Age
- 18 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 23 criteriaShow less
Who can take part
- Age over 18 years
- GERD symptoms lasting more than 6 months, not necessarily consecutive. They should at least have a typical GERD symptom (heartburn or regurgitation)
- Total acid exposure time> 6% in pH measurement study without PPI treatment
- Patients who do not want to take PPIs or with chronic consumption, defined as PPI consumption of more than 6 months (consecutive or not) in the last 2 years
- Response to PPI treatment, defined as an increase of> 10 points on the GERD-HRQL questionnaire 15 days after discontinuation of the PPI
- Written informed consent to participate in the study
Who cannot take part
- Esophagogastric surgery or previous endoscopic antireflux technique
- Previously known coagulopathy
- Oncological disease
- Severe psychiatric disorder
- Age> 75 years
- Patients with sliding hiatal hernia> 2 cm
- Presence of only atypical GERD symptoms
- Grade D peptic esophagitis
- Body mass index> 35 40 kg / m2
- Liver cirrhosis
- Pregnancy
- Incomplete relaxation of the LES in MAR (PIR> 15 mmHg)
- Absent peristalsis, defined as 100% failed waves with DCI <100 mmHg * cm * s in MAR
- Barrett's esophagus with dysplasia
- Esophageal strictures or ulcers
- Severe cardiopulmonary comorbidity (ASA functional class IV-V)
- Refusal to participate in the study
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The ARMA technique improves GORD-related quality of life with a low proportion of adverse effects.
The 2 groups in the trial
- (ARMA) antireflux ablation of the cardiac mucosaTreatment being tested
The ARMA (Ablation with electrocoagulation current or by argon gas fulguration) technique will be performed in patients assigned to this treatment arm.
- upper digestive endoscopyPlacebo, for comparison
Quality diagnostic upper gastrointestinal endoscopy will be performed without intervention in patients assigned to this treatment arm.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Double-blind, Placebo-controlled Clinical Trial on the Efficacy of Antireflux Ablation of the Cardiac Mucosa for the Treatment of Gastroesophageal Reflux Disease
- Publications
- Record updated
- 24 April 2025